Highlights Prostatype Genomics AB

Equities

PROGEN

SE0014684569

Market Closed - Nasdaq Stockholm Other stock markets 06:49:11 2024-04-30 am EDT			5-day change	1st Jan Change
0.0416 ^SEK	+7.22%		+1.96%	-56.21%

Apr. 18	Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala	CI
Apr. 17	Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala	Apr. 18	CI
Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®	Apr. 17	CI
Prostatype Genomics Wraps Up Prostate Cancer Genetic Test Study with Positive Results	Apr. 16	MT
Prostatype Genomics Announces Strong Positive Final Results from Multicentre Study with Prostatype®? in Spain	Apr. 16	CI
Prostatype Genomics AB Announces Strong Positive Final Results from Multicentre Study with Prostatype in Spain	Apr. 16	CI
Prostatype Genomics Enters into Collaboration with Professor E. David Crawford University of California San Diego, in Preparation for the Commercial Launch of Prostatype in the United States	Apr. 02	CI
Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Prostatype Genomics AB Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®	Dec. 22	CI
Prostatype Genomics Secures Prostate Cancer Test Order From Swiss Institution; Shares Surge	Nov. 01	MT
Prostatype Genomics AB Receives the First Order of Prostatype in Switzerland from One of the Country's Major University Hospitals	Nov. 01	CI
Prostatype Genomics AB Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics	23-10-30	CI
Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)	23-10-25	CI
Prostatype Genomics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Prostatype Genomics AB Provides Revenue Guidance for the Third Quarter of 2023	23-08-17	CI
Prostatype Genomics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Prostatype Genomics Enters Collaboration with Eurofins Megalab	23-03-29	CI
Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Prostatype Genomics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Prostatype Genomics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Prostatype Genomics AB Provides Sales Guidance for the Year 2022	22-11-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Prostatype Genomics AB

Equities

PROGEN

SE0014684569

Highlights

Filters